SCIENTIFIC POSTER 2016_Outcome of IVTY of Ocriplasmin for Symptomatic Vitreomacular Adhesion Mostafa Elgohary

Purpose:

To evaluate the rate of release of vitreomacular adhesion (VMA), anatomical changes and visual outcome following intravitreal ocriplasmin injection for the treatment of symptomatic VMA with and without full-thickness macular hole (FTMH).

Methods:

This is a retrospective, interventional, case-series of 12 eyes of 11 consecutive patients who received intravitreal injection of 0.125mg ocriplasmin (Jetrea; Alcon). Assessment included visual acuity, fundus examination and spectral domain optical coherence tomography at baseline and at each follow-up visit.

Results:

VMA release was achieved in 5 of 12 eyes (41.6%) by day 28, and in 7 of 12 eyes (58%) by day 136. Of the 2 eyes that had a FTMH, none achieved closure. Three eyes (25%) underwent pars plana vitrectomy and the 2 FTMHs closed after surgery. Outer retinal changes included the development of subfoveal fluid in 7 eyes (58%) and loss of the ellipsoid zone in 6 eyes (50%) but all resolved by 3 months. In those with VMA release, distortion and diplopia reduced in n (%) and visual improvement of >= 2 lines occurred in n (%). The median VA was …. & …. for pre and post injection, respectively (include p of Wilcoxon ranksum for pre and post VA).

Conclusions:

Intravitreal injection of ocriplasmin achieved successful release of VMA and improvement in visual acuity in the majority of patients and was associated with transient outer retinal changes. We had only 2 patients with FTMH and therefore could not make definite conclusion regarding the outcome of ocriplasmin use in those patients.

Contact Details:

Email: m.elgohary@doctors.org.uk
Cell Phone: +447939274217

Mostafa Elgohary